These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 37532782)

  • 1. Oral JAK inhibitor baricitinib effective in JIA.
    McHugh J
    Nat Rev Rheumatol; 2023 Sep; 19(9):539. PubMed ID: 37532782
    [No Abstract]   [Full Text] [Related]  

  • 2. The JAK1/2 inhibitor baricitinib suppresses eosinophil effector function and restricts allergen-induced airway eosinophilia.
    Luschnig P; Kienzl M; Roula D; Pilic J; Atallah R; Heinemann A; Sturm EM
    Biochem Pharmacol; 2021 Oct; 192():114690. PubMed ID: 34274356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Baricitinib: therapeutic potential for moderate to severe atopic dermatitis.
    Calabrese L; Malvaso D; Chiricozzi A; Tambone S; D'Urso DF; Guerriero C; Peris K
    Expert Opin Investig Drugs; 2020 Oct; 29(10):1089-1098. PubMed ID: 32703039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Repigmentation of vitiligo with oral baricitinib.
    Mumford BP; Gibson A; Chong AH
    Australas J Dermatol; 2020 Nov; 61(4):374-376. PubMed ID: 32491188
    [No Abstract]   [Full Text] [Related]  

  • 5. Effective treatment of oral lichen planus with the JAK inhibitor baricitinib.
    Moussa A; Colla T; Morrison B; Sinclair R
    Australas J Dermatol; 2022 May; 63(2):276-277. PubMed ID: 35213737
    [No Abstract]   [Full Text] [Related]  

  • 6. Janus kinase inhibitors ruxolitinib and baricitinib impair glycoprotein-VI mediated platelet function.
    Parra-Izquierdo I; Melrose AR; Pang J; Lakshmanan HHS; Reitsma SE; Vavilapalli SH; Larson MK; Shatzel JJ; McCarty OJT; Aslan JE
    Platelets; 2022 Apr; 33(3):404-415. PubMed ID: 34097573
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful treatment of alopecia areata-associated trachyonychia with baricitinib.
    Rózsa P; Degovics D; Baltás E; Gyulai R; Kemény L
    Int J Dermatol; 2024 Aug; 63(8):1089-1090. PubMed ID: 38514896
    [No Abstract]   [Full Text] [Related]  

  • 8. Successful use of baricitinib in the treatment of refractory rheumatoid arthritis-associated Sweet syndrome.
    Nousari Y; Wu BC; Valenzuela G
    Clin Exp Dermatol; 2021 Oct; 46(7):1330-1332. PubMed ID: 33914946
    [No Abstract]   [Full Text] [Related]  

  • 9. Baricitinib in Alopecia Areata.
    Messenger A; Harries M
    N Engl J Med; 2022 May; 386(18):1751-1752. PubMed ID: 35507486
    [No Abstract]   [Full Text] [Related]  

  • 10. Oral Baricitinib Restores Hair Loss in Alopecia Areata.
    Slomski A
    JAMA; 2022 Jun; 327(24):2386. PubMed ID: 35762995
    [No Abstract]   [Full Text] [Related]  

  • 11. Baricitinib Is First Approved COVID-19 Immunomodulatory Treatment.
    Rubin R
    JAMA; 2022 Jun; 327(23):2281. PubMed ID: 35727290
    [No Abstract]   [Full Text] [Related]  

  • 12. JAK-inhibitors for coronavirus disease-2019 (COVID-19): a meta-analysis.
    Chen CX; Wang JJ; Li H; Yuan LT; Gale RP; Liang Y
    Leukemia; 2021 Sep; 35(9):2616-2620. PubMed ID: 33990684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Janus kinase inhibitors in the treatment of pyoderma gangrenosum: case report and review.
    Grisé A; Valere LC; Weinstein D; Sami N
    Arch Dermatol Res; 2024 May; 316(6):238. PubMed ID: 38795155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Janus kinase inhibitors for atopic dermatitis: a promising treatment modality.
    Cartron AM; Nguyen TH; Roh YS; Kwatra MM; Kwatra SG
    Clin Exp Dermatol; 2021 Jul; 46(5):820-824. PubMed ID: 33484582
    [TBL] [Abstract][Full Text] [Related]  

  • 15. JAK inhibitors in refractory juvenile idiopathic arthritis-associated uveitis.
    Miserocchi E; Giuffrè C; Cornalba M; Pontikaki I; Cimaz R
    Clin Rheumatol; 2020 Mar; 39(3):847-851. PubMed ID: 31897953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world single centre use of JAK inhibitors across the rheumatoid arthritis pathway.
    Fitton J; Melville AR; Emery P; Nam JL; Buch MH
    Rheumatology (Oxford); 2021 Sep; 60(9):4048-4054. PubMed ID: 33331938
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Baricitinib: The Second FDA-Approved JAK Inhibitor for the Treatment of Rheumatoid Arthritis.
    Mogul A; Corsi K; McAuliffe L
    Ann Pharmacother; 2019 Sep; 53(9):947-953. PubMed ID: 30907116
    [No Abstract]   [Full Text] [Related]  

  • 18. Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database.
    Taylor PC; Takeuchi T; Burmester GR; Durez P; Smolen JS; Deberdt W; Issa M; Terres JR; Bello N; Winthrop KL
    Ann Rheum Dis; 2022 Mar; 81(3):335-343. PubMed ID: 34706874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Baricitinib as a treatment for myasthenia gravis: a case report.
    Iguchi M; Honjo J; Yamamoto T; Kanai K
    Neuromuscul Disord; 2024 Aug; 41():56-58. PubMed ID: 38954991
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of Janus kinase inhibitors in COVID-19: a prospective observational series in 522 individuals.
    Melikhov O; Kruglova T; Lytkina K; Melkonyan G; Prokhorovich E; Putsman G; Rodoman G; Vertkin A; Zagrebneva A; Stebbing J
    Ann Rheum Dis; 2021 Sep; 80(9):1245-1246. PubMed ID: 34099486
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.